Impact of the UGT1A1*28 allele on response to irinotecan: A systematic review and meta-analysis

Pharmacogenomics

Volumn 13, Issue 8, 2012, Pages 889-899

  Dias, Mafalda M ^a   McKinnon, Ross A ^b   Sorich, Michael J ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

irinotecan; meta analysis; pharmacogenetics; response; UGT1A1*28

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; PHARMACOLOGICAL BIOMARKER;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COHORT ANALYSIS; COLORECTAL CANCER; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; GENE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; UGT1A1 28 GENE; WILD TYPE; CHEMICALLY INDUCED DISORDER; DIARRHEA; GENETIC ASSOCIATION; GENETICS; NEOPLASM; NEUTROPENIA;

ALLELES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOMARKERS, PHARMACOLOGICAL; CAMPTOTHECIN; DIARRHEA; GENETIC ASSOCIATION STUDIES; GLUCURONOSYLTRANSFERASE; HOMOZYGOTE; HUMANS; NEOPLASMS; NEUTROPENIA;

EID: 84862003137     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.68     Document Type: Article

References (50)

1. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, Mcleod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst. 99(17), 1290-1295 (2007).
2. Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med. 11(1), 21-34 (2009). Evidence-based review of UGT1A1 genotyping including clinical utility considerations.
3. Hu ZY, Yu Q, Zhao YS. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur. J. Cancer 46(10), 1856-1865 (2010).
4. Hu ZY, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin. Cancer Res. 16(15), 3832-3842 (2010).
5. Innocenti F, Ratain M. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 7(8), 1211-1221 (2006).
6. Hoskins JM, Mcleod HL. UGT1A and irinotecan toxicity: keeping it in the family. J. Clin. Oncol. 27(15), 2419-2421 (2009).
7. Deeken JF, Slack R, Marshall JL. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics - to test or not to test, that is the question. Cancer 113(7), 1502-1510 (2008).
8. Winder T, Lenz H-J. Molecular predictive and prognostic markers in colon cancer. Cancer Treat. Rev. 36, 550-556 (2010).
9. Berg AO, Armstrong K, Botkin J et al. Recommendations from the EGAPP working group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet. Med. 11 (1), 15-20 (2009). Evaluation of Genomic Applications in Practice and Prevention working group recommendations.
10. Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 115(17), 3858-3867 (2009). Cost-effectiveness analysis of UGT1A1 testing.
11. Obradovic M, Mrhar A, Kos M. Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics 9(5), 539-549 (2008).
12. Kim H, Seo B, Kim J et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase, and uridine diphosphate glucuronosyltransferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Presented at: Annual Meeting of ASCO. FL, USA, 29 May-2 June 2009.
13. Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26(16), 2690-2698 (2008).
14. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91(4), 678-682 (2004).
15. Boige V, Mendiboure J, Pignon JP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-2005. J. Clin. Oncol. 28(15), 2556-2564 (2010).
16. Kweekel DM, Gelderblom H, van der Straaten T et al. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br. J. Cancer 99(2), 275-282 (2008).
17. McLeod HL, Sargent DJ, Marsh S et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from north American gastrointestinal intergroup trial N9741. J. Clin. Oncol. 28(20), 3227-3233 (2010).
18. Martinez-Balibrea E, Abad A, Martinez-Cards A et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br. J. Cancer 103(4), 581-589 (2010).
19. Ruzzo A, Graziano F, Loupakis F et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J. 8(4), 278-288 (2008).
20. Sugiyama T, Hirose T, Kusumoto S et al. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Oncol. Res. 18(7), 337-342 (2009).
21. Toffoli G, Cecchin E, Corona G et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24(19), 3061-3068 (2006).
22. Han JY, Lim HS, Shin ES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24(15), 2237-2244 (2006).
23. Carlini LE, Meropol NJ, Bever J et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res. 11(3), 1226-1236 (2005).
24. Glimelius B, Garmo H, Berglund A et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J. 11(1), 61-71 (2011).
25. Lara Jr PN, Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 27(15), 2530-2535 (2009).
26. Pillot GA, Read WL, Hennenfent KL et al. A Phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J. Thorac. Oncol. 1(9), 972-978 (2006).
27. Liu CY, Chen PM, Chiou TJ et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112(9), 1932-1940 (2008).
28. Schulz C, Heinemann V, Schalhorn A et al. UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J. Gastroenterol. 15(40), 5058-5066 (2009).
29. Takano M, Kato M, Yoshikawa T et al. Clinical significance of UDPglucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers. Oncology 76(5), 315-321 (2009).
30. Fuse N, Suenaga M, Yamaguchi T et al. First evaluation of the efficacy, safety, and drug-drug interaction of combination therapy of FOLFIRI and bevacizumab in UGT1A1 gene polymorphism of advanced and recurrent colorectal cancer. Presented at: 12th World Congress on Gastrointestinal Cancer, ESMO. Barcelona, Spain, 30 June-3 July 2010.
31. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7), 1-6 (2009).
32. Liberati A, Altman D, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 6(7), 1-28 (2009).
33. Stroup D, Berlin J, Morton S et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15), 2008-2012 (2000).
34. Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues of concern. Stat. Med. 27, 6547-6569 (2008).
35. Cecchin E, Innocenti F, D'Andrea M et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27 (15), 2457-2465 (2009).
36. Enzinger P, Fidias P, Regan E et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Presented at: 34th Congress of the European Society for Medical Oncology (ESMO). Stockholm, Sweden, 12-16 September 2008.
37. Etienne-Grimaldi M, Bennouna J, Formento J et al. Prospective pharmacogenetic analysis in advanced colorectal cancer (CRC) patients receiving first-line cetuximab-UFT-irinotecan therapy: importance of gene polymorphisms related to antibodydependent cellular cytotoxicity (ADCC). Presented at: Annual Meeting of ASCO. FL, USA, 29 May-2 June 2009.
38. Gamulin M, Jokic M, Grgic M, Kapitanovic S. Pharmacogenetic database of colorectal cancer patients in croatia - correlation with clinical data. Presented at: 34th Congress of the European Society for Medical Oncology (ESMO). Stockholm, Sweden, 12-16 September 2008.
39. Kularatne B, Marinaki A, Spicer J, Loganayagam A, Ross P. Pharmacogenetics of irinotecan: minimising toxicities and maximising clinical response. Presented at: 5th European Multidisciplinary Colorectal Cancer Congress EMCC. Nice, France, 28-30 March 2010.
40. Yang D, Pohl A, Zhang W et al. Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/- cetuximab (CB): The EPIC experience. Presented at: Annual Meeting of ASCO. FL, USA, 29 May-2 June 2009.
41. Zarate RN, Rodriguez J, Bandres E et al. Predictive value of Ile105Val polymorphism of the gluthatione-S-transferase P1 in patients with metastatic colorectal cancer (mCRC) treated with the triplet combination of irinotecan, oxaliplatin, and capecitabine. Presented at: Annual Meeting of ASCO. FL, USA, 29 May-2 June 2009.
42. Martinez-Balibrea E, Abad A, Valladares M et al. Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil. Presented at: Annual Meeting of ASCO. FL, USA, 29 May-2 June 2009.
43. Michaelis L, Ratain M. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer 6, 409-414 (2006).
44. Weber W. Assessing tumor response to therapy. J. Nucl. Med. 50(Suppl. 5), 1S-10S (2009).
45. Wu W, Sargent D. Choice of endpoints in cancer clinical trials. In: Oncology Clinical Trials: Successful Design, Conduct, and Analysis. Kelly W, Halabi S (Eds). Demos Medical Publishing, NY, USA, 35-42 (2010).
46. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11, 753-762 (2010).
47. Font A, Sanchez JM, Taron M et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest. New Drugs 21 (4), 435-443 (2003).
48. West S, King V, Carey T et al. Systems to rate the strength of scientific evidence. In: Evidence Report/Technology Assessment No. 47, A.H.R.Q. (Ed.). Research Triangle Institute - University of North Carolina, Evidence-based Practice Center, Rockville, MD, USA, 1-200 (2002). www.thecre.com/pdf/ahrq- system-strength.pdf
49. Review Manager (RevMan) [Computer Program]. Version 5.1. (2011). http://ims.cochrane.org/revman
50. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis, Version 2, Biostat. (2005). www.meta-analysis.com